RXi Pharmaceuticals Corporation (NASDAQ: RXII) is one of 199 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare RXi Pharmaceuticals Corporation to related companies based on the strength of its profitability, dividends, risk, valuation, earnings, analyst recommendations and institutional ownership.

Volatility & Risk

RXi Pharmaceuticals Corporation has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, RXi Pharmaceuticals Corporation’s rivals have a beta of 1.62, meaning that their average share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

1.7% of RXi Pharmaceuticals Corporation shares are owned by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 5.7% of RXi Pharmaceuticals Corporation shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for RXi Pharmaceuticals Corporation and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RXi Pharmaceuticals Corporation 0 0 0 0 N/A
RXi Pharmaceuticals Corporation Competitors 484 2289 6252 120 2.66

RXi Pharmaceuticals Corporation currently has a consensus target price of $1.71, suggesting a potential upside of 212.61%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 3.51%. Given RXi Pharmaceuticals Corporation’s higher possible upside, analysts plainly believe RXi Pharmaceuticals Corporation is more favorable than its rivals.

Earnings & Valuation

This table compares RXi Pharmaceuticals Corporation and its rivals revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
RXi Pharmaceuticals Corporation $0.02 -$8.99 -0.41
RXi Pharmaceuticals Corporation Competitors $220.75 -$39.68 5.00

RXi Pharmaceuticals Corporation’s rivals have higher revenue, but lower earnings than RXi Pharmaceuticals Corporation. RXi Pharmaceuticals Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares RXi Pharmaceuticals Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RXi Pharmaceuticals Corporation N/A -155.48% -102.55%
RXi Pharmaceuticals Corporation Competitors -3,978.87% -117.56% -43.68%

Summary

RXi Pharmaceuticals Corporation rivals beat RXi Pharmaceuticals Corporation on 6 of the 9 factors compared.

RXi Pharmaceuticals Corporation Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.